Silvestrol

Antineoplastic CAS# 697235-38-4

Silvestrol

Catalog No. BCC1948----Order now to get a substantial discount!

Product Name & Size Price Stock
Silvestrol: 5mg $4922 In Stock
Silvestrol: 10mg Please Inquire In Stock
Silvestrol: 20mg Please Inquire Please Inquire
Silvestrol: 50mg Please Inquire Please Inquire
Silvestrol: 100mg Please Inquire Please Inquire
Silvestrol: 200mg Please Inquire Please Inquire
Silvestrol: 500mg Please Inquire Please Inquire
Silvestrol: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Silvestrol

Number of papers citing our products

Chemical structure

Silvestrol

3D structure

Chemical Properties of Silvestrol

Cas No. 697235-38-4 SDF Download SDF
PubChem ID 11787114 Appearance Powder
Formula C34H38O13 M.Wt 654.66
Type of Compound N/A Storage Desiccate at -20°C
Synonyms (-)-Silvestrol
Solubility DMSO : ≥ 6.6 mg/mL (10.08 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name methyl (1R,2R,3S,3aR,8bS)-6-[[(2S,3R,6R)-6-[(1R)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate
SMILES COC1C(OC(CO1)C(CO)O)OC2=CC(=C3C(=C2)OC4(C3(C(C(C4C5=CC=CC=C5)C(=O)OC)O)O)C6=CC=C(C=C6)OC)OC
Standard InChIKey GVKXFVCXBFGBCD-QKDMMWSPSA-N
Standard InChI InChI=1S/C34H38O13/c1-40-20-12-10-19(11-13-20)34-27(18-8-6-5-7-9-18)26(30(38)42-3)29(37)33(34,39)28-23(41-2)14-21(15-24(28)47-34)45-32-31(43-4)44-17-25(46-32)22(36)16-35/h5-15,22,25-27,29,31-32,35-37,39H,16-17H2,1-4H3/t22-,25-,26-,27-,29-,31-,32-,33+,34+/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Silvestrol

DescriptionSilvestrol is isolated from the fruits and twigs of Aglaia foveolata, and is a specific eIF4A-targeting translation inhibitor.In Vitro:Silvestrol is a specific eIF4A-targeting translation inhibitor. Silvestrol exhibits significant cytotoxic activity against many human cancer cell lines, such as lung, prostate, and breast cancer with IC50 values ranging from 1 to 7 nM[1]. Silvestrol significantly reduces the number of LNCaP cell colonies. Silvestrol (30 nM, 120 nM) induces apoptosis in LNCaP cells, through the mitochondrial pathway. Apaf-1, Caspase-2, caspase-9, and caspase-10 are involved in Silvestrol-induced apoptosis but caspase-3 and 7 are not[2]. Silvestrol (50 nM) exerts an immediate inhibitory effect and causes near-static cell index compared with the control cells. Silvestrol (6.25 nM) enhances proliferation more than the vehicle control-treated cells, whereas a higher concentration of Silvestrol (50 nM) can inhibit cell proliferation. Silvestrol and episilvestrol display synergistic effects in combination with cisplatin[3]. Silvestrol induces caspase-3 activation and apoptotic cell death in a time- and dose-dependent manner. Silvestrol-mediated cell death is attenuated in ATG7-null mouse embryonic fibroblasts (MEFs) lacking a functional autophagy protein[4].In Vivo:Silvestrol (1.5 mg/kg, i.p.) does not adversely affect production of human IgG by xenografted B-lymphocytes in mice. Silvestrol significantly prolongs survival compared to vehicle. There is no such lymphocyte infiltration detected in the spleens of any of the Silvestrol-treated mice, and nor do these animals exhibit any other obvious signs of lymphoma upon necropsy[5].

References:
[1]. Chambers JM, et al. Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II. Org Lett. 2013 Mar 15;15(6):1406-9. [2]. Kim S, et al. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res. 2007 Jul-Aug;27(4B):2175-83. [3]. Daker M, et al. Inhibition of nasopharyngeal carcinoma cell proliferation and synergism of cisplatin with silvestrol and episilvestrol isolated from Aglaia stellatopilosa. Exp Ther Med. 2016 Jun;11(6):2117-2126. [4]. Chen WL, et al. Silvestrol induces early autophagy and apoptosis in human melanoma cells. BMC Cancer. 2016 Jan 13;16:17. [5]. Patton JT, et al. The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease. Oncotarget. 2015 Feb 20;6(5):2693-708. [6]. Wolfe AL, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature. 2014 Sep 4;513(7516):65-70. [7]. Wiegering A, et al. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer. Cancer Discov. 2015 Jul;5(7):768-781. [8]. Todt D, et al. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo. Antiviral Res. 2018 Sep;157:151-158.

Protocol

Kinase Assay [2]
The Apo-ONETM homogeneous caspase-3/7 assay kit is used to measure the activities of caspase-3 and -7. Cells (7×104 cells/mL) are treated with Silvestrol (15 nM, 30 nM, 60 nM, 120 nM, and 240 nM) or etoposide for 24 h in a black 96-well plate. Etoposide, which is known to activate caspases-3/7 in LNCaP cells, is used as a positive control for this assay. At the end of the treatment, lysis buffer and the substrate (Z-DEVD-rhodamine 110) are mixed and added to the cells. Upon sequential cleavage and removal of the DEVD peptides by caspase-3 and -7 activity and excitation at 499 nm, the rhodamine 110-leaving group becomes intensely fluorescent. The emission maximum is 521 nm. The amount of fluorescent product generated is proportional to the amount of caspase-3 and -7 cleavage activity present in the sample. The samples are measured in triplicate. Caspase-3 and -7 activity is indicated by net fluorescence[2].

Cell Assay [2]
The cells are seeded at a density of 7×104 cells/mL in 100-mm culture dishes and are treated with 30 nM or 120 nM concentrations of Silvestrol for 24 h. The cells are trypsinized, washed with PBS, and fixed with 1% (w/v) paraformaldehyde in PBS on ice for 30 min. After centrifugation, the cells are suspended in 70% (v/v) ethanol at −20°C until use. All ethanol is removed from the reaction tubes and cells are washed twice with PBS. The cells are processed for labeling with fluorescein-tagged deoxyuridine triphosphate nucleotide at 22°C-24°C overnight, washed, and incubated with propidium iodide/RNase A solution in the dark for 30 min at room temperature. The labeled cells are then analyzed by flow cytometry[2].

Animal Administration [5]
Mice[5] Peripheral blood mononuclear cells (PBMC) are injected intraperitoneally (IP) into SCID mice depleted of murine natural killer (NK) cells by pretreatment (plus weekly re-treatment) with anti-asialo (GM1). Engraftment is confirmed by hu-IgG ELISA. Treatments with vehicle (30% hydroxypropyl-β-cyclodextrin) or Silvestrol (1.5 mg/kg every 48 hr IP) begin 2 weeks post-engraftment[5].

References:
[1]. Chambers JM, et al. Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II. Org Lett. 2013 Mar 15;15(6):1406-9. [2]. Kim S, et al. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res. 2007 Jul-Aug;27(4B):2175-83. [3]. Daker M, et al. Inhibition of nasopharyngeal carcinoma cell proliferation and synergism of cisplatin with silvestrol and episilvestrol isolated from Aglaia stellatopilosa. Exp Ther Med. 2016 Jun;11(6):2117-2126. [4]. Chen WL, et al. Silvestrol induces early autophagy and apoptosis in human melanoma cells. BMC Cancer. 2016 Jan 13;16:17. [5]. Patton JT, et al. The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease. Oncotarget. 2015 Feb 20;6(5):2693-708. [6]. Wolfe AL, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature. 2014 Sep 4;513(7516):65-70. [7]. Wiegering A, et al. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer. Cancer Discov. 2015 Jul;5(7):768-781. [8]. Todt D, et al. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo. Antiviral Res. 2018 Sep;157:151-158.

Silvestrol Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Silvestrol Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Silvestrol

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.5275 mL 7.6376 mL 15.2751 mL 30.5502 mL 38.1878 mL
5 mM 0.3055 mL 1.5275 mL 3.055 mL 6.11 mL 7.6376 mL
10 mM 0.1528 mL 0.7638 mL 1.5275 mL 3.055 mL 3.8188 mL
50 mM 0.0306 mL 0.1528 mL 0.3055 mL 0.611 mL 0.7638 mL
100 mM 0.0153 mL 0.0764 mL 0.1528 mL 0.3055 mL 0.3819 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Silvestrol

Silvestrol inhibited protein synthesis in MDA-MB-231 breast and PC-3 prostate cancer cell lines with IC50 ~60 nM following a 1 h exposure) [1]. Silvestrol inhibited cell growth with an IC50 of 12.5-86 nM in four different HCC cell lines [3].
Silvestrol, a member of flavagline family of natural products from the genus of Aglaia exhibiting anti-cancer activity in vitro and in vivo and inhibiting translation initiation, was shown to be capable of modulating chemosensitivity in a mechanism-based mouse model.
Preclinical study: A previous study demonstrated that silvestrol showed antileukemia activity at nanomolar concentrations in both FLT3-wt overexpressing (THP-1) and FLT3-ITD (MV4-11) expressing AML cell lines (IC50 = 3.8 and 2.7 nM, respectively) and patients’ primary blasts [IC50 = ~12 nM (FLT3-wt) and ~5 nM (FLT3-ITD)]. Moreover, silvestrol was observed to efficiently inhibite FLT3 translation resulting in a decrese of FLT3 protein expression by 80–90%. Animal study indicated that the median survival of silvestrol-treated mice significantly increased (silvestrol-treated vs vehicle-treated = 63 vs 29 days postengraftment) [2]. Another study showed that silvestrol could increase the activities of apoptosis and caspase 3/7. In vivo, the antitumor effect was found with 0.4 mg/kg silvestrol, and the survival of tumor-bearing mice was improved with a median survival time of 42 and 28 days in the silvestrol and control groups, respectively [3].
Clinical study: Currently, there is no clinical data about the anti-cancer efficacy of silvestrol. A grant application proposeed to pursue a Phase I clinical trial to assess the safety, maximum tolerated dose, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of silvestrol in patients with relapsed, refractory Chronic lymphocytic leukemia (Pre-Clinical and Clinical Development of Silvestrol in Chronic Lymphocytic).
References:
[1] Cencic R, Carrier M, Galicia-Vázquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, Porco JA Jr, Pelletier J Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One. 2009;4(4):e5223. doi: 10.1371/journal.pone.0005223.
[2] Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J Hematol Oncol. 2013;6:21. doi: 10.1186/1756-8722-6-21.
[3] Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Patel T. Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One. 2013;8(9):e76136. doi: 10.1371/journal.pone.0076136.

Featured Products
New Products
 

References on Silvestrol

The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.[Pubmed:25393910]

Oncotarget. 2015 Feb 20;6(5):2693-708.

Treatment options for patients with Epstein-Barr Virus-driven lymphoproliferative diseases (EBV-LPD) are limited. Chemo-immunotherapeutic approaches often lead to immune suppression, risk of lethal infection and EBV reactivation, thus it is essential to identify agents that can deliver direct anti-tumor activity while preserving innate and adaptive host immune surveillance. Silvestrol possesses direct anti-tumor activity in multiple hematologic malignancies while causing minimal toxicity to normal mononuclear cells. However, the effects of Silvestrol on immune function have not been described. We utilized in vitro and in vivo models of EBV-LPD to simultaneously examine the impact of Silvestrol on both tumor and normal immune function. We show that Silvestrol induces direct anti-tumor activity against EBV-transformed lymphoblastoid cell lines (LCL), with growth inhibition, decreased expression of the EBV oncogene latent membrane protein-1, and inhibition of the downstream AKT, STAT1 and STAT3 signaling pathways. Silvestrol promoted potent indirect anti-tumor effects by preserving expansion of innate and EBV antigen-specific adaptive immune effector subsets capable of effective clearance of LCL tumor targets in autologous co-cultures. In an animal model of spontaneous EBV-LPD, Silvestrol demonstrated significant therapeutic activity dependent on the presence of CD8-positive T-cells. These findings establish a novel immune-sparing activity of Silvestrol, justifying further exploration in patients with EBV-positive malignancies.

The natural compound silvestrol is a potent inhibitor of Ebola virus replication.[Pubmed:27864075]

Antiviral Res. 2017 Jan;137:76-81.

The DEAD-box RNA helicase eIF4A, which is part of the heterotrimeric translation initiation complex in eukaryotes, is an important novel drug target in cancer research because its helicase activity is required to unwind extended and highly structured 5'-UTRs of several proto-oncogenes. Silvestrol, a natural compound isolated from the plant Aglaia foveolata, is a highly efficient, non-toxic and specific inhibitor of eIF4A. Importantly, 5'-capped viral mRNAs often contain structured 5'-UTRs as well, which may suggest a dependence on eIF4A for their translation by the host protein synthesis machinery. In view of the recent Ebola virus (EBOV) outbreak in West Africa, the identification of potent antiviral compounds is urgently required. Since Ebola mRNAs are 5'-capped and harbor RNA secondary structures in their extended 5'-UTRs, we initiated a BSL4 study to analyze Silvestrol in EBOV-infected Huh-7 cells and in primary human macrophages for its antiviral activity. We observed that Silvestrol inhibits EBOV infection at low nanomolar concentrations, as inferred from large reductions of viral titers. This correlated with an almost complete disappearance of EBOV proteins, comparable in effect to the translational shutdown of expression of the proto-oncoprotein PIM1, a cellular kinase known to be affected by Silvestrol. Effective Silvestrol concentrations were non-toxic in the tested cell systems. Thus, Silvestrol appears to be a promising first-line drug for the treatment of acute EBOV and possibly other viral infections.

Silvestrol induces early autophagy and apoptosis in human melanoma cells.[Pubmed:26762417]

BMC Cancer. 2016 Jan 13;16:17.

BACKGROUND: Silvestrol is a cyclopenta[b]benzofuran that was isolated from the fruits and twigs of Aglaia foveolata, a plant indigenous to Borneo in Southeast Asia. The purpose of the current study was to determine if inhibition of protein synthesis caused by Silvestrol triggers autophagy and apoptosis in cultured human cancer cells derived from solid tumors. METHODS: In vitro cell viability, flow cytometry, fluorescence microscopy, qPCR and immunoblot was used to study the mechanism of action of Silvestrol in MDA-MB-435 melanoma cells. RESULTS: By 24 h, a decrease in cyclin B and cyclin D expression was observed in Silvestrol-treated cells relative to control. In addition, Silvestrol blocked progression through the cell cycle at the G2-phase. In Silvestrol-treated cells, DAPI staining of nuclear chromatin displayed nucleosomal fragments. Annexin V staining demonstrated an increase in apoptotic cells after Silvestrol treatment. Silvestrol induced caspase-3 activation and apoptotic cell death in a time- and dose-dependent manner. Furthermore, both Silvestrol and SAHA enhanced autophagosome formation in MDA-MB-435 cells. MDA-MB-435 cells responded to Silvestrol treatment with accumulation of LC3-II and time-dependent p62 degradation. Bafilomycin A, an autophagy inhibitor, resulted in the accumulation of LC3 in cells treated with Silvestrol. Silvestrol-mediated cell death was attenuated in ATG7-null mouse embryonic fibroblasts (MEFs) lacking a functional autophagy protein. CONCLUSIONS: Silvestrol potently inhibits cell growth and induces cell death in human melanoma cells through induction of early autophagy and caspase-mediated apoptosis. Silvestrol represents a natural product scaffold that exhibits potent cytotoxic activity and could be used for the further study of autophagy and its relationship to apoptosis in cancer cells.

Inhibition of nasopharyngeal carcinoma cell proliferation and synergism of cisplatin with silvestrol and episilvestrol isolated from Aglaia stellatopilosa.[Pubmed:27284293]

Exp Ther Med. 2016 Jun;11(6):2117-2126.

Nasopharyngeal carcinoma (NPC) is a type of tumour that arises from the epithelial cells that line the surface of the nasopharynx. NPC is treated with radiotherapy and cytotoxic chemotherapeutic drugs such as cisplatin and 5-fluorouracil. However, current strategies are often associated with potential toxicities. This has prompted efforts to identify alternative methods of treatment. The present study aimed to investigate Silvestrol and epiSilvestrol-mediated inhibition of cell proliferation in human NPC cells. The growth kinetics of NPC cells treated with Silvestrol or epiSilvestrol were monitored dynamically using a real-time, impedance-based cell analyzer, and dose-response profiles were generated using a colorimetric cell viability assay. Furthermore, apoptosis was evaluated using flow cytometry and high content analysis. In addition, flow cytometry was performed to determine cell cycle distribution. Finally, the effects of combining Silvestrol or epiSilvestrol with cisplatin on NPC cells was examined. Apoptosis was not observed in Silvestrol and epiSilvestrol-treated NPC cells, although cell cycle perturbation was evident. Treatment with both compounds induced a significant increase in the percentage of cells in the G2/M phase, as compared with the control. In vitro cultures combining Silvestrol or epiSilvestrol with cisplatin showed synergistic effects against NPC cells. The results of the present study suggested that Silvestrol and epiSilvestrol had an anti-tumour activity in NPC cells. Silvestrol and epiSilvestrol, particularly in combination with cisplatin, merit further investigation, so as to determine the cellular mechanisms underlying their action(s) as anti-NPC agents.

Description

Silvestrol is a eukaryotic translation initiation factor 4A (eIF4A) inhibitor isolated from the fruits and twigs of Aglaia foveolata. Silvestrol induces autophagy and caspase-mediated apoptosis.

Keywords:

Silvestrol,697235-38-4,(-)-Silvestrol,Natural Products,FLT3, buy Silvestrol , Silvestrol supplier , purchase Silvestrol , Silvestrol cost , Silvestrol manufacturer , order Silvestrol , high purity Silvestrol

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: